Charles Schwab Portfolio holdings
Charles Schwab Corporation, founded in 1971 by Charles R. Schwab and headquartered in Westlake, Texas, is a leading financial services firm that revolutionized retail investing by offering low-cost brokerage services. Initially disrupting the industry with discount commissions, it has grown into a powerhouse providing a wide array of services, including trading platforms, robo-advisors, retirement accounts, and banking products, managing hundreds of billions in client assets. Known for its user-friendly technology and customer-centric approach, Schwab caters to individual investors, financial advisors, and institutions, notably expanding through its 2020 acquisition of TD Ameritrade. With a mission to democratize investing, Charles Schwab remains a dominant force in the shift toward accessible, self-directed wealth management.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Moderna
MRNA
|
+$269M |
| 2 |
Amazon
AMZN
|
+$242M |
| 3 |
Apple
AAPL
|
+$215M |
| 4 |
Amgen
AMGN
|
+$212M |
| 5 |
Citizens Financial Group
CFG
|
+$193M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Vanguard FTSE Emerging Markets ETF
VWO
|
+$210M |
| 2 |
ALXN
Alexion Pharmaceuticals
ALXN
|
+$195M |
| 3 |
iShares GSCI Commodity Dynamic Roll Strategy ETF
COMT
|
+$154M |
| 4 |
MXIM
Maxim Integrated Products
MXIM
|
+$127M |
| 5 |
WORK
Slack Technologies, Inc.
WORK
|
+$115M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 20.58% |
| 2 | Financials | 13.47% |
| 3 | Healthcare | 12.09% |
| 4 | Consumer Discretionary | 10.78% |
| 5 | Industrials | 8.88% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
NAGE
2976
Niagen Bioscience
NAGE
$241M
| $771K | ﹤0.01% |
122,812
+5,362
| +5% | +$44.2K |
|
|
WEBR
2977
DELISTED
Weber Inc.
WEBR
| $771K | ﹤0.01% |
+43,796
| New | +$703K |
|
2978
Commercial Vehicle Group
CVGI
$129M
| $769K | ﹤0.01% |
81,222
-204
| -0.3% | -$1.93K |
|
|
LONA
2979
LeonaBio Inc
LONA
$73.9M
| $767K | ﹤0.01% |
8,177
-7,022
| -46% | -$715K |
|
2980
Genie Energy
GNE
$384M
| $766K | ﹤0.01% |
117,185
| – | – |
|
2981
Quantum Corp
QMCO
$962M
| $765K | ﹤0.01% |
7,384
+199
| +3% | +$23.4K |
|
|
GNTY
2982
DELISTED
Guaranty Bancshares
GNTY
| $764K | ﹤0.01% |
21,297
+1,576
| +8% | +$53.6K |
|
|
DRRX
2983
DELISTED
DURECT Corp
DRRX
| $761K | ﹤0.01% |
59,418
+2,019
| +4% | +$27.4K |
|
2984
Home Bancorp
HBCP
$570M
| $760K | ﹤0.01% |
19,647
| – | – |
|
|
NMTR
2985
DELISTED
9 Meters Biopharma
NMTR
| $759K | ﹤0.01% |
29,157
+3,226
| +12% | +$76K |
|
2986
NVE Corp
NVEC
$564M
| $753K | ﹤0.01% |
11,763
-13
| -0.1% | -$924 |
|
|
NPKI
2987
NPK International
NPKI
$1.18B
| $753K | ﹤0.01% |
227,933
-399,864
| -64% | -$1.13M |
|
|
EGIO
2988
DELISTED
Edgio, Inc. Common Stock
EGIO
| $752K | ﹤0.01% |
7,890
-14,085
| -64% | -$1.48M |
|
2989
Blue Ridge Bankshares
BRBS
$336M
| $747K | ﹤0.01% |
42,451
-22
| -0.1% | -$384 |
|
2990
BeyondSpring
BYSI
$38.2M
| $747K | ﹤0.01% |
47,373
-88
| -0.2% | -$1.58K |
|
2991
Pulse Biosciences
PLSE
$3.21B
| $747K | ﹤0.01% |
34,554
-258
| -0.7% | -$5.55K |
|
2992
First Bancorp
FNLC
$399M
| $744K | ﹤0.01% |
25,501
+77
| +0.3% | +$2.23K |
|
2993
UNIFI
UFI
$125M
| $742K | ﹤0.01% |
33,817
-65,417
| -66% | -$1.49M |
|
|
FLXN
2994
DELISTED
Flexion Therapeutics, Inc.
FLXN
| $738K | ﹤0.01% |
120,880
-195,445
| -62% | -$1.22M |
|
|
INFI
2995
DELISTED
Infinity Pharmaceuticals, Inc.
INFI
| $737K | ﹤0.01% |
215,450
-122
| -0.1% | -$376 |
|
|
KZR
2996
DELISTED
Kezar Life Sciences
KZR
| $736K | ﹤0.01% |
8,511
-490
| -5% | -$32.4K |
|
2997
Atlanticus Holdings
ATLC
$1.49B
| $734K | ﹤0.01% |
13,823
| – | – |
|
|
ZH
2998
Zhihu
ZH
$274M
| $733K | ﹤0.01% |
+13,223
| New | +$794K |
|
2999
Alta Equipment Group
ALTG
$238M
| $732K | ﹤0.01% |
53,260
+4,284
| +9% | +$56.1K |
|
|
LUNA
3000
DELISTED
Luna Innovations Incorporated
LUNA
| $731K | ﹤0.01% |
76,875
| – | – |
|
Similar funds
Charles Schwab's Q3 2021 Portfolio in Review
As of Q3 2021, Charles Schwab held 3,610 positions worth $306B, up 1.6% from $301B the previous quarter. Its ten largest holdings account for 17% of the portfolio.
Charles Schwab's Q3 2021 filing shows 202 new, 2,185 increased, 922 reduced and 109 closed positions. Its largest new stake was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M. The largest sale was Vanguard FTSE Emerging Markets ETF, an estimated $210M.
By sector, the portfolio is most concentrated in Technology at 21% of assets, up from 20% a quarter earlier, followed by Financials and Healthcare.
- Charles Schwab's largest Q3 2021 buy was iShares Core 1-5 Year USD Bond ETF: 3,548,215 shares worth $181M.
- Charles Schwab added most to Moderna in Q3 2021, an estimated $269M increase.
- Charles Schwab's biggest Q3 2021 reduction was Vanguard FTSE Emerging Markets ETF, cutting an estimated $210M.
- Charles Schwab fully exited Alexion Pharmaceuticals in Q3 2021, selling an estimated $195M.
- Charles Schwab's ten largest holdings make up 17% of its $306B portfolio in Q3 2021.
- Charles Schwab opened 202 new positions and closed 109 in Q3 2021.
- Charles Schwab's portfolio value rose 1.6% quarter-over-quarter to $306B.
Based on Charles Schwab's 13F filing for Q3 2021, filed 16 Nov 2021.